Comparison of Combined Therapy of Intravitreal Injection of Bevacizumab and Pegaptanib versus Mono-therapy (The MAAM Study) - MAAM-Study
Phase 1
- Conditions
- Subjects of either gender aged > 50 years, diagnosed with subfoveal CNV secondary to AMD, a predominantly occult lesion composition, and with best corrected visual acuity of 20/40 to 20/200 in the absence of subfoveal atrophy or scarring in the trial eye.
- Registration Number
- EUCTR2006-001389-18-AT
- Lead Sponsor
- udwig Boltzmann Institute forRetinology and Biomicroscopic Laser Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
age > 50 years
predominantly occult CNV
greatest diameter of the lesion < 5400µm
distance acuity > 0.1
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Any of the following will exclude a subject from the study:
Complicating general disorders inflicting with healing process
vision threatening diseases other than CNV
Prior treatment for CNV
Ophthalmic surgery within 4 weeks
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method